The two complementary approaches to prevent DYRK1A activity by pharmacological inhibition or genetic ablation specifically in adult CMs improved cardiac function after MI, supporting that DYRK1A knockdown after injury can lead to therapeutic benefits. The gene discussed is DYRK1A; the disease is myocardial infarction.